))
Episode: 1 - Bo Wiinberg on Bridging Research and Trials with Cell-Based Therapies
Manage episode 510380455 series 3693726
Are cell therapies the key to bridging the gap between discovery research and clinical trials? In the inaugural episode of the Bioprocessing Unfiltered podcast, Bo Wiinberg, chief business development officer at Novo Nordisk Foundation Cellerator, sat with Ran Zheng, CEO of Landmark Bio and shared his expert insight on the promise cell therapies hold for diseases with only treatments but no cures. Their conversation covers the challenges of navigating cell therapy programs through pre-clinical and clinical development journeys, how Cellerator is creating innovative spaces in CMC and manufacturing to fulfill critical needs in the translational space, and what a sustainable global cell therapy manufacturing landscape looks in 5-10 years.
Links from this episode:
Bioprocessing Summit
Landmark Bio
Novo Nordisk Foundation Cellerator
Bioprocessing Unfiltered: Covering both upstream and downstream processing, analytics, AI and digitization, cell and gene therapy and more, Bioprocessing Unfiltered is your insider’s pass to the researchers tackling—and solving—the day-to-day challenges in the bioprocessing industry.
Chapters
1. Setting the Stage: Cell Therapy’s Promise (00:00:00)
2. Bo’s Path: Academia, Biotech, Pharma (00:02:30)
3. Why Cell Therapies Stall: CMC and Cost (00:04:45)
4. Bridging Discovery to GMP: A New Model (00:07:30)
5. Harmonizing Standards and Regulators (00:11:00)
6. One-Stop Hub for Translation (00:14:45)
7. Designing the Facility: PD First (00:18:20)
One episode
Share
